<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Speakers &#8211; Canadian Stroke Congress</title>
	<atom:link href="https://strokecongress.canadianstroke.ca/speaker_category/speakers/feed/" rel="self" type="application/rss+xml" />
	<link>https://strokecongress.canadianstroke.ca</link>
	<description>May 24-25, 2026</description>
	<lastBuildDate>Sat, 23 Nov 2024 17:38:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://strokecongress.canadianstroke.ca/wp-content/uploads/2025/06/cropped-Screenshot-2025-06-19-at-2.09.48 PM-32x32.png</url>
	<title>Speakers &#8211; Canadian Stroke Congress</title>
	<link>https://strokecongress.canadianstroke.ca</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Dr. Paul Albert</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/paul-albert/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Tue, 30 Jul 2024 04:19:22 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1760</guid>

					<description><![CDATA[Dr. Paul R. Albert obtained his Ph.D. in Pharmacology from Harvard (1985) and did post-doctoral studies with Drs. Herbert and Civelli (Vollum Institute, Portland OR), where he cloned several dopamine and serotonin receptor genes.&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Paul R. Albert obtained his Ph.D. in Pharmacology from Harvard (1985) and did post-doctoral studies with Drs. Herbert and Civelli (Vollum Institute, Portland OR), where he cloned several dopamine and serotonin receptor genes. His first academic position was as Assistant then Associate Professor, Dept. of Pharmacology and Therapeutics, McGill University. In 1995, he was awarded the CIHR/Novartis Michael Smith Chair in Neuroscience at University of Ottawa, and is currently Full Professor and Senior Scientist at the Ottawa Hospital Research Institute. He is also Associate Director of Neuroscience, and has served as Director of the Neuroscience Graduate Program. He has served on several editorial boards (Neuroreport, Endocrinology, J. Biol. Chem., Int. J. Neuropsychopharmacol.), grants panels (CIHR, HSFC, etc.) and organized international meetings (ISAD, ISSR, CCNP, GPCR Retreat). He is currently Editor-in-Chief of the Journal of Psychiatry and Neuroscience, in which he has the most cited paper and is 4th most cited author. He is also a founding member of the HSFO Centre for Stroke Recovery and HSFC Canadian Partnership for Stroke Recovery. He has published 157 research papers with 10,600 citations and H-index of 52 (Scopus 2024).</p>
<p>Dr. Albert’s research is at the interface between molecular biology and psychiatry and focuses on the mechanistic link between the transcriptional regulation of genes of the serotonin and dopamine systems and mental illness. Since cloning the 5-HT1A and dopamine-D2 receptor genes, his laboratory has identified signaling mechanisms and novel transcription factors involved in their regulation. In collaboration with psychiatrists, his laboratory has identified novel functional polymorphisms in the 5-HT1A and dopamine-D2 receptor genes and their association with depression, suicide and treatment response. More recently, his laboratory has begun to use animal models to evaluate the roles of these transcription factors in vivo. For example, in probing the molecular mechanisms that regulate the 5-HT1A gene his lab identified human 5-HT1A variant (rs6295) that increases 5-HT1A autoreceptor expression and is associated with SSRI-resistant depression. To test whether these transcription changes really affect depression they have knocked them out in serotonin neurons of adult mice. This results in SSRI-resistant anxiety and depression-like behaviors. The lab is now testing whether other types of antidepressants or direct stimulation of serotonin neurons will reverse the depression in these mice.</p>
<p>In addition to genetic studies, Dr. Albert has also established a new mouse model of post-stroke depression and currently examine pharmacological, exercise and optogenetic approaches to enhance recovery. This mouse model responds to SSRI but not to exercise and chronic SSRI induces a regrowth of serotonin projections to the injured brain that correlates with recovery. The Albert lab is currently addressing the mechanisms of this regrowth and its importance in behavioral recovery.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Kit Beyer</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/kit-beyer/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Mon, 29 Jul 2024 04:05:15 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1804</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Sandra Billinger</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-sandra-billinger/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Mon, 29 Jul 2024 04:04:50 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1805</guid>

					<description><![CDATA[Dr. Sandra Billinger, PT, PhD, is Professor, Vice Chair, Stroke Translational Research; Assistant Director, Neuroimaging Core, KU Alzheimer’s Disease Research Center; and co-PI and co-Director of an NIH-funded T32 Brain Health Training Program at&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Sandra Billinger, PT, PhD, is Professor, Vice Chair, Stroke Translational Research; Assistant Director, Neuroimaging Core, KU Alzheimer’s Disease Research Center; and co-PI and co-Director of an NIH-funded T32 Brain Health Training Program at the University of Kansas (KU) Medical Center. Dr. Billinger has mentored numerous graduate students, postdoctoral fellows and junior faculty at the local, national and international level.</p>
<p>Her laboratory is the Research in Exercise and Cardiovascular Health Laboratory research and has focused on exercise interventions (R01HD093694, R01AG053952, R01AR071263, R01AG049749) to optimize vascular health and brain aging in older adults and people post-stroke. Additional projects have been funded through R21, K01, R01s, American Heart Association (AHA) and the American Physical Therapy Association’s Academy of Cardiovascular and Pulmonary Physical Therapy. Dr. Billinger is an internationally renowned speaker on exercise testing and interventions with an emphasis on people living with stroke. Dr. Billinger has over 100 publications in peer-reviewed journals. She served as Chair, Stroke Rehabilitation and Recovery Committee for the AHA Stroke Council and was the lead author for the AHA Scientific Statement, Physical Activity and Exercise Recommendations for Stroke Survivors in 2014. Dr. Billinger has served as a member of the AHA/ASA Oversight Committee for the Bugher Foundation Centers of Excellence in Stroke Collaborative Research for Regeneration, Resilience, and Secondary Prevention (2015-2019) and now serves as an Oversight Committee member for the Centers of Excellence in Hemorrhagic Stroke (2020-current). Dr. Billinger was awarded the AHA Stroke Council Lecture Award in 2016 and Excellence in Neurologic Research from the Academy of Neurologic Physical Therapy, American Physical Therapy Association (2021) and the Kansas City Central Exchange STEMMy Educator Award in 2021. She was recognized by the World Stroke Organization Board of Directors in 2022 as one of the outstanding women who have made important and significant contributions to the field of stroke and brain health around the world. In 2023, Dr. Billinger received the distinguished KU Scholarly Research Achievement Award and from her alma mater, Fort Hays State University, the Alumni Achievement Award.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Gregory Bix</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/gregory-bix/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Mon, 29 Jul 2024 04:03:03 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1808</guid>

					<description><![CDATA[Prof. Gregory Bix, M.D., Ph.D., F.A.H.A., a physician scientist, is the Director of the Clinical Neuroscience Research Center, the Vada Odom Reynolds Chair in Stroke Research, and Professor and Vice Chair of Clinical and&#8230;]]></description>
										<content:encoded><![CDATA[<p>Prof. Gregory Bix, M.D., Ph.D., F.A.H.A., a physician scientist, is the Director of the Clinical Neuroscience Research Center, the Vada Odom Reynolds Chair in Stroke Research, and Professor and Vice Chair of Clinical and Translational Research and academic affairs in the Departments of Neurosurgery and Neurology at Tulane University School of Medicine, New Orleans, LA, USA. Prof. Bix also holds a number of international academic appointments; Professor at the University of Manchester (England), Clinical Senior Lecturer at University of Glasgow (Scotland), Adjunct Professor, Queensland University of Technology (Australia). He is a Fellow of the American Heart Association and has served on a number of prestigious international and national grant, editorial board and meeting committees. He is a productive (~ 100 publications) multi-grant (NIH, AHA, etc.) awarded principal investigator and is an expert in the fields of stroke, dementia, COVID-19 and long covid. In stroke, Prof. Bix has pioneered the study of the pathology and therapeutic potential of the extracellular matrix and its receptors as novel stroke therapies resulting in more than a dozen patents awarded world-wide. Prof. Bix serves on the scientific advisory board of several pharmaceutical companies. Prof. Bix has won many career awards including the recent Spirit of Tulane award and has given more than one hundred invited seminars, lectures and keynote addresses.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Sandra Black</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-sandra-black/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Mon, 29 Jul 2024 04:02:43 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1761</guid>

					<description><![CDATA[Sandra E Black, O.C., O.Ont., Hon.DSc., MD, FRCP(C), FRSC, FANA, FAHA, FAAN, is a Professor of Medicine (Neurology Division) at Sunnybrook Health Sciences Centre, University of Toronto, and is an internationally known cognitive and&#8230;]]></description>
										<content:encoded><![CDATA[<p>Sandra E Black, O.C., O.Ont., Hon.DSc., MD, FRCP(C), FRSC, FANA, FAHA, FAAN, is a Professor of Medicine (Neurology Division) at Sunnybrook Health Sciences Centre, University of Toronto, and is an internationally known cognitive and stroke neurologist, actively engaged in &gt; 70 pharma trials in the last 3 decades. She has published &gt;650 peer publications in a research career bridging dementia and stroke, using standardized, cognitive, functional and behavioural measures, and neuropathology to study brain-behavior relationships. Career totals: peer-reviewed: 665 group: 85; invited: 74; abstracts: 924; lectures: 725; H-index: 109 (Scopus) 145 (Google Scholar); GS Citations: 90,541. She has mentored 50 postdoctoral fellows, 20 PhDs &amp; 20 MSc students along with several hundred medical students and trainees in neurology. She was a recipient of the Distinguished Achievement Award of American Academy of Neurology&#8217;s Society of Cognitive and Behavioural Neurology and also UBC’s 2022 Margolese Brain Disorders prize, recognizing Canadians who have made outstanding contributions to amelioration and treatment of brain disorders. She was also appointed Member of the Order of Ontario in 2011 and Officer in the Order of Canada in 2015 for her contributions to Alzheimer’s disease, stroke and vascular dementia. She is ranked 8th nationally and 281 in the world of the top 1000 female scientists by Research.com, a leading academic platform for researchers (2024).</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Mark Boulos</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/mark-boulos/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Mon, 29 Jul 2024 04:01:31 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1807</guid>

					<description><![CDATA[Dr. Mark Boulos is a Stroke &#38; Sleep Neurologist and Associate Professor at Sunnybrook Health Sciences Centre and the University of Toronto. Dr. Boulos serves as Medical Lead for the Sunnybrook Sleep Laboratory and&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Mark Boulos is a Stroke &amp; Sleep Neurologist and Associate Professor at Sunnybrook Health Sciences Centre and the University of Toronto. Dr. Boulos serves as Medical Lead for the Sunnybrook Sleep Laboratory and Program Director for the Sleep Neurology Fellowship Program at the University of Toronto. Dr. Boulos oversees a productive research program that investigates the association of sleep disorders with TIA/stroke &amp; other neurological disorders, as well as examines home sleep monitoring, normative sleep data, and novel treatment interventions for managing sleep disorders.</p>
<p>In 2020, Dr. Boulos was awarded by the American Academy of Neurology the Wayne Hening Sleep Medicine Investigator Award in recognition of outstanding achievements in Sleep Science research. Dr. Boulos has published more than 80 peer-reviewed journal articles in many high impact journals such as Lancet Respiratory Medicine, Neurology, Stroke, Chest, Sleep Medicine Reviews, and Sleep. In addition, he has secured funding on dozens of grants, approximating more than 4.5 million dollars in funding as PI/co-PI. Dr. Boulos’ research is supported by the Canadian Institutes of Health Research, Heart and Stroke Foundation, RLS Foundation, Branch Out Neurological Foundation, the Innovation Fund of the Academic Health Sciences Centres of Ontario, and several industry partners.</p>
<p>Moreover, Dr. Boulos has delivered numerous invited lectures at international and national conferences, and his work has also led to appearances with many major media outlets such as Yahoo!, CTV news, Toronto Star, Globe and Mail, as well as podcasts with the American Academy of Sleep Medicine, Manulife Insurance, the CBC, and Zoomer Radio.</p>
<p>Furthermore, he has been a mentor to many trainees, and most of his students are authors of the resulting publications. Since starting at Sunnybrook, he has supervised nearly 90 research trainees at all levels of training, from undergraduates to post-doctoral candidates. His outstanding teaching has been recognized by teaching awards, and he serves as a full member of the School of Graduate Studies at the University of Toronto.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Doug Cook</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-doug-cook/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Sun, 28 Jul 2024 04:16:21 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1799</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Dale Corbett</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/dr-dale-corbett/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Sun, 28 Jul 2024 04:14:03 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1776</guid>

					<description><![CDATA[Dr. Dale Corbett is Professor of Neurosciences (Emeritus) in the Department of Cellular and Molecular Medicine at the University of Ottawa. Dr. Corbett obtained his PhD in psychology from Concordia University followed by post-doctoral&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Dale Corbett is Professor of Neurosciences (Emeritus) in the Department of Cellular and Molecular Medicine at the University of Ottawa. Dr. Corbett obtained his PhD in psychology from Concordia University followed by post-doctoral studies at McGill University. His first faculty appointment was at Harvard University where he became interested in stroke research. In 1985, he moved to Memorial University where his laboratory became well known for pioneering research on the protective effects of prolonged, mild hypothermia that culminated in the use of &#8220;therapeutic hypothermia &#8221; in the treatment of cardiac arrest and perinatal asphyxia. He then changed research directions to focus on recovery of sensory-motor function following stroke where he has made several important translational discoveries regarding the importance of early and intensive rehabilitation. While at Memorial, Dr. Corbett developed the Stroke Program in Neurorecovery (SPiN), that was designed to inform basic biomedical and clinical trainees about each other’s research areas and help break down existing preclinical and clinical silos. In 2010, Dr. Corbett joined the Department of Cellular and Molecular Medicine at the University of Ottawa and became the Scientific Director of the Heart and Stroke Foundation, Canadian Partnership for Stroke Recovery. Over his career he has published nearly 180 papers in leading journals related to stroke and brain repair. He has received many awards, including an Alfred P. Sloan Fellowship at Harvard University, an award that recognizes the most promising young neuroscientists in the USA and Canada. He was the inaugural recipient of the Paul Morley Mentorship Award by the Canadian Stroke Network in recognition of his efforts in training the next generation of stroke researchers. In 2006, he gave the Raymond T. Hnatyshyn lecture at the Canadian Stroke Congress. Dr. Corbett held a Tier I Canada Research Chair in Stroke and Neuroplasticity at Memorial University and was named a fellow of the Canadian Academy of Health Sciences in 2011. In 2019, he received the Outstanding Neurorehabilitation Clinician Scientist Award from the American Society of Neurorehabilitation. Dr. Corbett continues to publish papers related to stroke recovery while maintaining several research collaborations and mentoring young scientists in Canada and abroad.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Ms. Jesse Dollimont</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/jesse-dollimont/</link>
		
		<dc:creator><![CDATA[Holly Vogel]]></dc:creator>
		<pubDate>Sat, 27 Jul 2024 16:01:33 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=2857</guid>

					<description><![CDATA[Jesse Dollimont MTA, NMT has been practicing music therapy in Alberta since 2017. She has recently stepped into a new role as a music therapist in the elementary education program at Renfrew Educational Services&#8230;]]></description>
										<content:encoded><![CDATA[<p>Jesse Dollimont MTA, NMT has been practicing music therapy in Alberta since 2017. She has recently stepped into a new role as a music therapist in the elementary education program at Renfrew Educational Services in Calgary, Alberta. As part of the therapy team she provides direct clinical intervention and assessments; as well as collaborating and consulting with classrooms, families, and the other therapists on our team to develop specialized programming and to support students diverse needs and goals. Previously she worked as part of the team at JB Music Therapy in Calgary, Alberta; providing music therapy intervention and supporting program development in neurologic rehabilitation, mental health, continuing care, burn treatment, education and early development programs, and community wellness programs. She is also a sessional instructor at the WHEAT (Winnipeg Holistic Expressive Arts Therapy) Institute. She is focused on a neuroscience informed and neuro-affirming approach in music therapy intervention; and views the therapeutic application of music as a powerful agent for supporting health and healing as it enhances our experiences of development, communication, recovery, connection, and community care.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Numa Dancause</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/dr-numa-dancause/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Sat, 27 Jul 2024 04:04:35 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1393</guid>

					<description><![CDATA[Numa Dancause Bsc(PT), PhD, is Professor and Associate Chair of the Department of Neurosciences of the UdeM; research axis director of the Fonds de Recherche du Quebec – Santé Centre Interdisciplinaire de Recherche sur&#8230;]]></description>
										<content:encoded><![CDATA[<p>Numa Dancause Bsc(PT), PhD, is Professor and Associate Chair of the Department of Neurosciences of the UdeM; research axis director of the Fonds de Recherche du Quebec – Santé Centre Interdisciplinaire de Recherche sur le Cerveau et l’Apprentissage (CIRCA), co-lead of the Canadian Platform for Trials in Non-Invasive Brain Stimulation (CanStim) overseeing research in animal models and member of the Union Neuroscience et Intelligence artificielle Quebec (UNIQUE), the strategic research cluster of the Fonds de Recherche du Quebec – Nature et Technologie.</p>
<p>With his original training in physical therapy, Numa carefully aligns his experimental work in animals to human studies to provides complementary data that address critical clinical questions. His lab uses a variety of electrophysiological and neuroanatomical techniques in different models (rat, capuchin, vervet and macaque) to study motor control, plasticity supporting motor recovery after brain injury such as stroke, and the effects of rehabilitation and neuromodulation on this plasticity. His leadership is well demonstrated by numerous invitations to give lectures, implication in national and international meetings and contributions to several international recommendation papers in the field of stroke recovery. Publications:68; Google H-index:29; i10-index:48; Citations:4140.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Andrew Demchuk</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-andrew-demchuk/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Sat, 27 Jul 2024 04:03:20 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1756</guid>

					<description><![CDATA[Dr. Andrew Demchuk is a Professor in the Department of Clinical Neurosciences for the Cumming School of Medicine, University of Calgary. He is also a stroke neurologist and Director of the Calgary Stroke Program.&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Andrew Demchuk is a Professor in the Department of Clinical Neurosciences for the Cumming School of Medicine, University of Calgary. He is also a stroke neurologist and Director of the Calgary Stroke Program. His major national responsibility is Chair of the Board of Directors, Canadian Stroke Consortium (Canada’s professional organization for stroke physicians).</p>
<p>Dr. Demchuk completed his medical degree (with distinction) from the University of Saskatchewan in 1993, followed by neurology residency from the University of Calgary (1993-97); and fellowship in cerebrovascular disease (1997-99) from the University of Texas-Houston.</p>
<p>Dr. Demchuk’s primary research interests focus on vascular imaging and clinical trials in acute stroke. Univ of Calgary has contributed several imaging scales and tools to help stroke clinicians worldwide better select patients for acute stroke treatment in the emergency setting. His favorite responsibility is the training of stroke fellows. The Calgary Stroke Fellowship program has trained over 110 fellows from 25 countries. 45 of which, practice stroke neurology across Canada.</p>
<p>Throughout his career he has received a number of awards, most recently in 2023, he was awarded the Raymond J Hnatyshyn Lecturer for stroke excellence in Canada and very recently received the Government of Alberta inaugural Dr. William Cochrane Health System Innovation Award.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Marika Demers</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-marika-demers/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Sat, 27 Jul 2024 04:02:41 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1803</guid>

					<description><![CDATA[Dr. Marika Demers is an assistant professor in the School of Rehabilitation, at the Université de Montréal and an emerging researcher at the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal. She is&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Marika Demers is an assistant professor in the School of Rehabilitation, at the Université de Montréal and an emerging researcher at the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal. She is a Junior 1 research scholar from the Fonds de la Recherche du Québec – health. Dr. Demers received her BSc in occupational therapy from the Université de Montréal, and her MSc and PhD in Rehabilitation Sciences at McGill University. She completed a post-doctoral fellowship at the Motor Behavior and Neurorehabilitation Laboratory in the Division of Biokinesiology and Physical Therapy at the University of Southern California. She is also a trained occupational therapist with clinical expertise in stroke rehabilitation. Her research interests involve the use of health technologies to better assess and optimize arm and hand motor recovery for people post-stroke.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. PJ Deveraux</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/dr-pj-deveraux/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Sat, 27 Jul 2024 04:01:45 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1838</guid>

					<description><![CDATA[Dr. Devereaux is a cardiologist, perioperative care physician, and clinical epidemiologist. He is the Director of the Division of Perioperative Care at McMaster University. He is a Senior Scientist and the Scientific Leader of&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Devereaux is a cardiologist, perioperative care physician, and clinical epidemiologist. He is the Director of the Division of Perioperative Care at McMaster University. He is a Senior Scientist and the Scientific Leader of the Anesthesiology, Perioperative Medicine, and Surgical Research Group at the Population Health Research Institute (PHRI). He is the Nominated Principal Applicant of the Accelerating Clinical Trials (ACT) Consortium, which is the Pan-Canadian Clinical Trials Consortium funded by the Canadian Institutes of Health Research (CIHR). He also holds a Tier 1 Canadian Research Chair in Perioperative Medicine.</p>
<p>Dr. Devereaux is a full Professor at McMaster University. He is the President of the Society of Perioperative Research and Care. Dr. Devereaux has published &gt;450 peer reviewed papers and &gt;90 book chapters, editorials, and commentaries, including 17 in the New England Journal of Medicine, 13 in the Lancet, and 11 in JAMA. He has an h-index of 122. He has given &gt;1000 lectures and research presentations in 41 countries. Dr. Devereaux’s research program focuses on major vascular complications during and after surgery. He has led many large international randomized trials and prospective cohort studies focused on major perioperative vascular complications.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Sean Dukelow (co-chair)</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/sean-dukelow/</link>
		
		<dc:creator><![CDATA[strokecongress]]></dc:creator>
		<pubDate>Sat, 27 Jul 2024 04:00:58 +0000</pubDate>
				<guid isPermaLink="false">http://www.coffeecreamthemes.com/themes/evnt/wordpress/?post_type=speaker&#038;p=342</guid>

					<description><![CDATA[University of Calgary, Lead Principal Investigator, CanStroke Recovery Clinical Trials Platform]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;">University of Calgary, Lead Principal Investigator, CanStroke Recovery Clinical Trials Platform</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Jodi Edwards (co-chair)</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/jodi-edwards/</link>
		
		<dc:creator><![CDATA[strokecongress]]></dc:creator>
		<pubDate>Fri, 26 Jul 2024 17:17:15 +0000</pubDate>
				<guid isPermaLink="false">http://www.coffeecreamthemes.com/themes/evnt/wordpress/?post_type=speaker&#038;p=340</guid>

					<description><![CDATA[University of Ottawa Heart Institute, Lead Principal Investigator, StrokeCog Clinical Trials Training Platform]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;">University of Ottawa Heart Institute, Lead Principal Investigator, StrokeCog Clinical Trials Training Platform</span></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Thalia Field</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/thalia-field/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Thu, 25 Jul 2024 04:01:02 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1757</guid>

					<description><![CDATA[Dr. Thalia Field is a stroke neurologist and clinician-researcher at the University of British Columbia in Vancouver, Canada, where she is an Associate Professor and holds a Sauder Family/Heart and Stroke Professorship of Stroke&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Thalia Field is a stroke neurologist and clinician-researcher at the University of British Columbia in Vancouver, Canada, where she is an Associate Professor and holds a Sauder Family/Heart and Stroke Professorship of Stroke Research, focusing on clinical trials and stroke in younger adults with a focus on cerebral venous thrombosis and congenital heart disease.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Hillel Finestone</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/hillel-finestone/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Thu, 25 Jul 2024 04:00:08 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1794</guid>

					<description><![CDATA[Dr. Hillel Finestone is a specialist in Physical Medicine and Rehabilitation, or physiatrist. He graduated from McGill Medical School and received Physical Medicine and Rehabilitation specialty training at the Universities of Ottawa and Michigan.&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Hillel Finestone is a specialist in Physical Medicine and Rehabilitation, or physiatrist. He graduated from McGill Medical School and received Physical Medicine and Rehabilitation specialty training at the Universities of Ottawa and Michigan. He is a Professor in the Department of Medicine, Division of Physical Medicine and Rehabilitation at the University of Ottawa, Director of Stroke Rehabilitation Research at the Elisabeth Bruyere Hospital, Bruyere Continuing Care and Consultant at the Ottawa Hospital Rehabilitation Centre.</p>
<p>Dr. Finestone treats out-patients in the multi-disciplinary stroke rehabilitation setting of the Elisabeth Bruyere Hospital, Ottawa, Ontario, Canada. He also treats patients experiencing musculoskeletal and neurologic pain.</p>
<p>Dr. Finestone’s stroke research interests include: 1) Virtual Reality stroke rehabilitation technology to enhance exercise and balance- (patients play video games), 2) Driving and Stroke &#8211; he is the editor of the Section on Cerebrovascular diseases (including Stroke) &#8211; CMA Driver’s Guide, and invited member of the medical advisory committee of the Ministry of Transportation of the Province of Ontario, 3) Technology to assist toileting in stroke, disabled and geriatric populations. He has published many articles and book chapters. He is the recipient of the 2021 Best Paper Original Research – International Award by PM&amp;R – The Journal of Injury, Function and Rehabilitation for his study on sitting balance exercise using virtual reality training for stroke rehabilitation inpatients.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Allan Garland</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-allan-garland/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Wed, 24 Jul 2024 04:05:50 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1793</guid>

					<description><![CDATA[Allan Garland is Professor in the departments of Internal Medicine and Community Health Sciences at the University of Manitoba, and an Adjunct Scientist at the Manitoba Centre for Health Policy. He received a B.S.&#8230;]]></description>
										<content:encoded><![CDATA[<p>Allan Garland is Professor in the departments of Internal Medicine and Community Health Sciences at the University of Manitoba, and an Adjunct Scientist at the Manitoba Centre for Health Policy. He received a B.S. from the University of Michigan, M.A. from Harvard University, and M.D. from the University of Chicago where he also completed his Internal Medicine residency and fellowship in Pulmonary &amp; Critical Care Medicine. Following his training, in 1993 Allan joined the faculty at the Robert Wood Johnson Medical School in New Jersey, and in 2001 moved to the Case Western Reserve University School of Medicine, in Cleveland. During his 18 years at those institutions, he was the director of their Medical Intensive Care Units. He joined the faculty at the University of Manitoba in 2007, and was co-head of the Section of Critical Care Medicine from 2012-2021. His research interests include: (1) the epidemiology and long-term outcomes of critical illness, (2) relationships between medical care organization and clinical outcomes, (3) end-of-life care, (4) practice variation, and (5) statistical methods in observational research.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Mayank Goyal</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/dr-mayank-goyal/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Wed, 24 Jul 2024 04:04:59 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1839</guid>

					<description><![CDATA[Mayank Goyal is a Professor in the Department of Radiology and Clinical Neurosciences at the University of Calgary. He also holds the Heart and Stroke Foundation Chair in Stroke Research. Dr. Goyal’s passion and&#8230;]]></description>
										<content:encoded><![CDATA[<p>Mayank Goyal is a Professor in the Department of Radiology and Clinical Neurosciences at the University of Calgary. He also holds the Heart and Stroke Foundation Chair in Stroke Research. Dr. Goyal’s passion and main research interest is acute stroke imaging, workflow and intervention. With &gt;400 peer-review manuscripts (including first author papers in NEJM, Lancet Neurology, Radiology, Circulation, ANJR, Stroke), &gt;50 editorials and opinion pieces, over 400 abstracts and &gt;200 invite lectureships, Mayank has been an integral contributor in furthering the field of Stroke intervention research. He led ESCAPE and SWIFT PRIME (both published in NEJM); the HERMES collaboration (&gt;20 high impact publications including in Lancet, JAMA); ESCAPE-NA1 (published in Lancet) and has recently completed ESCAPE-NEXT and ESCAPE-MeVO trials. A citation index of &gt;45000, an h-index of 83 and an i10 index of 338 (google scholar, Jan 2022) are testimony to Dr. Goyal’s vast contribution and influence in the world of Stroke research. He has received several honours and awards including the Outstanding Contributions in Research Award (American Society of Neuroradiology, 2020), and the Lifetime Contribution Award (Canadian Association of Radiology, 2018). He is also a Fellow of the esteemed Canadian Academy of Health Sciences and Fellow of the Royal Society of Canada. He has recently launched a worldwide platform to accelerate stroke research: letsgetproof.com.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dr. Le-Anne Greer</title>
		<link>https://strokecongress.canadianstroke.ca/speaker/drs-leanne-greer/</link>
		
		<dc:creator><![CDATA[Dean Wiebe]]></dc:creator>
		<pubDate>Wed, 24 Jul 2024 04:03:58 +0000</pubDate>
				<guid isPermaLink="false">https://strokecongress.canadianstroke.ca/?post_type=speaker&#038;p=1758</guid>

					<description><![CDATA[Dr. Lee-Anne Greer is a psychologist at the Queen Elizabeth Hospital in Charlottetown, PEI. She has worked with individuals who have experienced stroke for over 20 years, and has been with the PEI Organized&#8230;]]></description>
										<content:encoded><![CDATA[<p>Dr. Lee-Anne Greer is a psychologist at the Queen Elizabeth Hospital in Charlottetown, PEI. She has worked with individuals who have experienced stroke for over 20 years, and has been with the PEI Organized Stroke Program since its beginning in 2009. She specializes in clinical psychology and neuropsychology. She also works with the Cardiac Rehab program in PEI, offering sessions on mental health and stress management. She has been a member of the Canadian Stroke Best Practice Recommendations writing group on VCI, and consulted on the latest revision of the Post-Stroke Mood and Depression recommendations.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
